Vasopressin

Overview

Vasopressin, also known as arginine vasopressin (AVP) or antidiuretic hormone (ADH), is a cyclic nonapeptide neurohormone synthesized primarily in the magnocellular and parvocellular neurons of the hypothalamic paraventricular nucleus (PVN) and supraoptic nucleus (SON). It is one of the most phylogenetically ancient signaling molecules, with homologs identified across vertebrates and invertebrates dating back over 700 million years.

Vasopressin's classical physiological roles center on water homeostasis and cardiovascular regulation. As the primary antidiuretic hormone, it acts on the kidneys to promote water reabsorption, concentrating urine and maintaining plasma osmolality within a narrow range. At higher concentrations, vasopressin acts as a potent vasoconstrictor, contributing to blood pressure maintenance — a property utilized clinically in the management of vasodilatory shock.

Like oxytocin, vasopressin has gained significant research attention for its roles beyond classical endocrine functions. Beginning with landmark studies in prairie voles demonstrating vasopressin's essential role in male pair bonding and territorial behavior, research has expanded to investigate vasopressin's contributions to human social cognition, aggression, stress reactivity, and psychiatric conditions.

Vasopressin and oxytocin are evolutionary paralogs — they arose from a gene duplication event in the ancestral vasotocin gene. This shared ancestry explains their remarkable structural similarity (differing at only 2 of 9 amino acid positions) and their overlapping but distinct roles in social behavior and physiology.

Structure and Sequence

Vasopressin is a cyclic nonapeptide with a disulfide bridge:

Sequence: Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH₂

• Molecular formula: C₄₆H₆₅N₁₅O₁₂S₂
• Molecular weight: 1,084.23 g/mol
• CAS Number: 113-79-1
• Disulfide bridge: Between Cys1 and Cys6, forming the characteristic tocin ring
• C-terminal: Amidated glycine (Gly-NH₂)

Comparison to oxytocin:

Position	Vasopressin	Oxytocin
3	Phe (phenylalanine)	Ile (isoleucine)
8	Arg (arginine)	Leu (leucine)
All other positions	Identical	Identical

The arginine at position 8 (hence "arginine vasopressin") is present in most mammals; some species have lysine at this position (lysine vasopressin, found in pigs). The phenylalanine at position 3 contributes to vasopressin's different receptor binding profile compared to oxytocin.

Species variants:

• Arginine vasopressin (AVP): Most mammals including humans
• Lysine vasopressin (LVP): Pigs and some other suids
• Arginine vasotocin (AVT): Non-mammalian vertebrates (the ancestral form)

Mechanism of Action

Receptor Subtypes

Vasopressin acts through three distinct receptor subtypes, all G-protein coupled receptors:

V1a Receptor (V1aR):

• Coupling: Gq/11 — phospholipase C activation, IP3/DAG signaling, intracellular calcium release
• Distribution: Vascular smooth muscle, liver, platelets, brain (lateral septum, amygdala, hippocampus)
• Functions: Vasoconstriction, hepatic glycogenolysis, platelet aggregation, social behavior, anxiety, aggression
• CNS role: The primary mediator of vasopressin's social behavioral effects

V1b Receptor (V1bR / V3R):

• Coupling: Gq/11
• Distribution: Anterior pituitary corticotrophs, brain (hippocampus, amygdala), pancreas
• Functions: ACTH release (stress response), insulin/glucagon secretion, anxiety and aggressive behavior
• CNS role: Modulation of HPA axis stress reactivity

V2 Receptor (V2R):

• Coupling: Gs — adenylyl cyclase activation, cAMP elevation
• Distribution: Renal collecting duct principal cells, vascular endothelium
• Functions: Water reabsorption (via aquaporin-2 insertion), release of von Willebrand factor and factor VIII from endothelium
• Clinical relevance: Target of desmopressin (DDAVP) for diabetes insipidus and nocturnal enuresis

Antidiuretic Mechanism

Vasopressin's antidiuretic action is the most well-characterized:

1. Plasma osmolality increase (or blood volume decrease) stimulates vasopressin release from the posterior pituitary
2. AVP binds V2 receptors on renal collecting duct principal cells
3. Gs-coupled cAMP increase activates protein kinase A
4. PKA phosphorylates aquaporin-2 (AQP2) water channels stored in intracellular vesicles
5. AQP2-containing vesicles translocate to and fuse with the apical membrane
6. Water permeability of the collecting duct increases dramatically
7. Water moves from tubular lumen into the hypertonic medullary interstitium
8. Concentrated urine is produced; plasma osmolality decreases

Social Behavior Modulation

Vasopressin's social behavioral effects are primarily mediated through central V1a receptors:

• Pair bonding: V1aR in the ventral pallidum is necessary for partner preference formation in male prairie voles
• Social recognition: V1aR in the lateral septum mediates social memory
• Aggression and territoriality: V1aR in the anterior hypothalamus modulates resident-intruder aggression
• Stress and anxiety: V1a and V1b receptors in the amygdala and septum influence anxiety-like behavior

Research Summary

Area	Study	Key Finding	Reference
Pair bonding	Prairie vole V1aR studies	V1aR expression in ventral pallidum is necessary and sufficient for male pair bonding	Young et al., 1999; Lim et al., 2004
Human social cognition	Intranasal AVP in humans	Enhanced encoding of social facial cues, sex-dependent effects on social communication	Thompson et al., 2006
Autism	AVPR1A gene association	Polymorphisms in V1a receptor gene associated with autism spectrum traits	Kim et al., 2002; Yirmiya et al., 2006
Autism treatment	Balovaptan (V1aR antagonist) Phase 2	Initial positive signal but failed Phase 3 efficacy for ASD social function	Bolognani et al., 2019; Roche, 2020
Septic shock	VASST trial (n=778)	Low-dose vasopressin + norepinephrine reduced mortality in less-severe septic shock subgroup	Russell et al., 2008 (NEJM)
Cardiac arrest	AHA guidelines	Vasopressin as alternative to epinephrine in cardiac arrest resuscitation protocols	Multiple, updated periodically
Diabetes insipidus	Desmopressin (DDAVP)	V2R-selective analog is standard treatment for central diabetes insipidus	Clinical standard of care
Aggression	V1b knockout mice	V1bR deletion reduces aggressive behavior in male mice	Wersinger et al., 2002
Stress axis	V1bR in pituitary	V1bR mediates ACTH release, modulating cortisol response to stress	Lolait et al., 2007

Pharmacokinetics

Endogenous vasopressin:

• Half-life: approximately 10-35 minutes in plasma
• Clearance: hepatic and renal; vasopressinase in plasma
• Basal plasma levels: approximately 1-4 pg/mL
• Osmolar threshold for release: approximately 280-285 mOsm/kg
• Stimuli for release: increased plasma osmolality, decreased blood volume, decreased blood pressure, pain, nausea, stress

Exogenous vasopressin (Pitressin/Vasostrict):

• Administration: Intravenous infusion (vasodilatory shock); intramuscular (diagnostic use)
• Onset: immediate (IV)
• Dosing (septic shock): 0.01-0.04 units/minute continuous IV infusion
• Duration: effects persist 30-60 minutes after discontinuation

Desmopressin (DDAVP) — the V2R-selective analog:

• Administration: Intranasal, oral tablet, sublingual, or parenteral
• Half-life: approximately 1.5-2.5 hours (longer than native AVP due to structural modifications)
• V2 selectivity: approximately 3,000x more selective for V2R over V1aR
• Modifications: Deamination at Cys1, D-arginine at position 8

Intranasal vasopressin (research):

• Typical research dose: 20-40 IU per session
• CNS effects: peak behavioral effects at approximately 30-60 minutes post-administration
• Duration: behavioral effects last approximately 1-3 hours

Common Discussion Topics

Vasopressin vs. Oxytocin in Social Behavior

While oxytocin is popularly associated with prosocial behavior, vasopressin's social roles are more closely tied to social vigilance, territoriality, and mate-guarding. Some researchers have proposed a complementary model: oxytocin facilitates approach behavior and social reward, while vasopressin promotes social vigilance and defensive social behavior. However, this dichotomy is an oversimplification, and the two systems interact extensively.

Sex Differences

Vasopressin's social behavioral effects show pronounced sex differences. In rodent models, vasopressin's effects on pair bonding, aggression, and social recognition are often more robust in males. This may relate to androgen-dependent regulation of V1a receptor expression and vasopressin synthesis in the bed nucleus of the stria terminalis and medial amygdala.

Vasopressin System and Psychiatric Disorders

Alterations in the vasopressin system have been implicated in multiple psychiatric conditions:

• Autism spectrum disorder (AVPR1A gene polymorphisms)
• Depression (elevated AVP in depression; V1b antagonists as potential antidepressants)
• PTSD (enhanced vasopressin signaling in stress circuits)
• Antisocial personality and aggression

Despite these associations, pharmacological targeting of the vasopressin system has proven challenging clinically. The failure of balovaptan (a V1aR antagonist) in Phase 3 trials for autism illustrates the complexity of translating receptor-level understanding into therapeutic benefit.

Clinical Use in Critical Care

Vasopressin's role in critical care medicine — particularly for vasodilatory shock and cardiac arrest — is well-established but distinct from its research applications in social behavior. The vasopressor properties mediated by V1a receptors in vascular smooth muscle make it valuable for blood pressure support when catecholamine responses are impaired.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines for exogenous vasopressin (Vasostrict). Always consult a qualified healthcare professional.

Indication	Dose	Route	Frequency
Vasodilatory shock (septic shock)	0.01-0.04 units/min	Continuous IV infusion	Titrate to effect (do not exceed 0.07 units/min)
Cardiac arrest (ACLS)	40 units	IV push (single dose)	Once (replaces first or second dose of epinephrine)
Diabetes insipidus (diagnostic/acute)	5-10 units	IM or SC	2-3 times daily as needed
GI variceal bleeding (off-label)	0.2-0.4 units/min	Continuous IV infusion	Up to 72 hours (with nitroglycerin to reduce ischemia)

Important notes: Vasopressin for chronic diabetes insipidus has been largely replaced by desmopressin, which has greater antidiuretic selectivity and negligible vasopressor activity. In shock, vasopressin is used as an adjunct to catecholamine vasopressors. Excessive doses can cause mesenteric and digital ischemia. The synthetic analog desmopressin is preferred for most antidiuretic indications.

Related Compounds

• Oxytocin — Differs from vasopressin by only two amino acids; evolutionary paralog with complementary social functions
• GnRH — Another hypothalamic neuropeptide involved in reproductive and behavioral regulation
• PE-22-28 — A synthetic peptide studied for mood regulation, relevant to vasopressin's roles in anxiety and depression